The initial focus of development is on PT-1 and TOP-1 programs. Each of these programs aim to deliver a breakthrough solution where other approaches have failed or do not exist.
| Program | Discovery | Pre-Clinical | Phase 1 | |
|---|---|---|---|---|
| Oral Delivery Platform | PT-1 EPO | |||
| PT-2 Octreotide | ||||
| PT-3 GLP-1 Agonist | ||||
| Therapeutics | Top-1 Skin Graft (Donor) | |||
| Top-2 Diabetic Wound | ||||
| Top-3 Burns (2nd Degree) | ||||
| Regenerative Medicine | AIPCs | |||
| T1 Diabetes Autologous Transplant | ||||
| Key | 2021-2023 | 2023-2024 |
|---|
Imagine’s three platforms form the foundation of a multi-year scientific inquiry that will lead to many discoveries and therapies to benefit a multitude of patients. With research programs targeting diseases where there are currently ineffective or no treatments, Imagine Pharma is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Pre-Clinical | Phase 1 |
|---|---|---|---|
| 2nd Generation Oral Delivery System | |||
| Additional Oral Biologics | |||
| Comprehensive Lung Healing Initiative | |||
| Comprehensive Bowel Initiative | |||
| Personalized Blood Vessel |
|||
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Imagine Pharma newsroom.
Our team has decades of drug discovery and development experience in the industry and are working to bring to market transformative first-in-class treatments.
Get to know the team committed to developing innovative treatments for patients.